Search
forLearn 1 of 2
All learn results →Research 10 of 103
- Baricitinib (Olumiant)
- Baricitinib (Olumiant)
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Shedding light on therapeutics in alopecia and their relevance to COVID-19
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- European expert consensus statement on the systemic treatment of alopecia areata
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Baricitinib as the first systemic treatment for severe alopecia areata